Autoimmune epilepsies

Current Opinion in Neurology

Volumn 24, Issue 2, 2011, Pages 146-153

  Irani, Sarosh R ^a   Bien, Christian G ^b   Lang, Bethan ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

auto antibodies; CASPR2; epilepsy; GAD; LGI1; NMDA; VGKC

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; ANTICONVULSIVE AGENT; AXONIN 1; CASPR2 PROTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; IMMUNOGLOBULIN; LGI1 PROTEIN; N METHYL DEXTRO ASPARTIC ACID; PEPTIDES AND PROTEINS; PREDNISOLONE; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ACUTE ENCEPHALITIS WITH REFRACTORY REPETITIVE PARTIAL SEIZURE; ANTICONVULSANT THERAPY; ARTICLE; AUTOIMMUNE DISEASE; DEVASTATING EPILEPTIC ENCEPHALOPATHY; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; EPILEPSY; FACIOBRACHIAL DYSTONIC SEIZURE; FEBRILE INFECTION RELATED EPILEPSY SYNDROME; HEMISPHERECTOMY; HOMEOSTASIS; HUMAN; IMMUNOTHERAPY; MYOKYMIA; NEW ONSET REFRACTORY STATUS EPILEPTICUS; PATHOGENICITY; RADIOIMMUNOASSAY; RASMUSSEN SYNDROME; TEMPORAL LOBE EPILEPSY; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CONTACTINS; ENCEPHALITIS; EPILEPSY; HUMANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEINS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79953058806     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283446f05     Document Type: Article

References (50)

1. Berg AT, Berkovic S, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-685.
2. Berg AT, Mathern GW, Bronen RA, et al. Frequency, prognosis and surgical treatment of structural abnormalities seen with magnetic resonance imaging in childhood epilepsy. Brain 2009;132:2785-2797.
3. Palace J, Lang B. Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 2000;69:711-714.
4. Bauer J, Bien C. Encephalitis and epilepsy. Semin Immunopathol 2009;31:537-544.
5. Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010;23:144-150.
6. Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 2007;69:1236-1244. (Pubitemid 47429024)
7. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-712. (Pubitemid 38295483)
8. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62:1177-1182. (Pubitemid 38456513)
9. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and Contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-2748.
10. Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008;71:1647-1648.
11. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005;65:1730-1736.
12. Majoie M, de Baets M, Renier W, et al. Antibodies to voltage-gated potassium channels in epilepsy. Epilepsy Res 2006;71:135-141. (Pubitemid 44419592)
13. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede LGI1-antibody limbic encephalitis. Ann Neurol (in press).
14. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010;5:S77-S80.
15. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776-785.
16. Barajas RF, Collins E, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with antivoltage-gated potassium-channel antibody. Epilepsia 2010;51:473-477.
17. Geschwind MD,Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008;65:1341-1346.
18. Dalmau J, Tüzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D- aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36. (Pubitemid 46214241)
19. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
20. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predomi nantly nonparaneoplastic disorder of both sexes. Brain 2010;133:1655-1667.
21. Florance NR, David RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-18.
22. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009;66:458-464.
23. Johnson N, Henry C, Fessle AJ, et al. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010;75: 1480.
24. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-5875.
25. Dale RC, Irani SR, Brilot F, et al. NMDA receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66:704-709.
26. Samarasekera SR, Vincent A, Welch JL, et al. Course and outcome of acute limbic encephalitis with negative voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry 2007;78:391-394. (Pubitemid 46580548)
27. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptorin limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67-76.
28. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.
29. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005;128:454-471. (Pubitemid 40380182)
30. Bien CG, Widman G, Urbach H, et al. The natural history of Rasmussen's encephalitis. Brain 2002;125:1751-1759.
31. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002;51:311-318. (Pubitemid 34206287)
32. Bauer J, Elger CE, Hans VH, et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol 2007;62:67-80. (Pubitemid 47235282)
33. Schwab N, Bien CG, Waschbisch A, et al. CD8+Tcell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 2009;132:1236-1246.
34. Thilo B, Stingele R, Knudsen K, et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol 2009;5:458-462.
35. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553-2563.
36. Liimatainen S, PeltolaM, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010;51:760-767.
37. Errichiello L, Perruolo G, Pascarella A, et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients. J Neuroimmunol 2009;211:20-123.
38. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470-478.
39. Nociti V, Frisullo G, Tartaglione T, et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol 2010;17:e5.
40. Mata S, Muscas GC, Naldi I, et al. Nonparaneoplastic limbic encephalitis associated with antiglutamic acid decarboxylase antibodies. J Neuroimmunol 2008;199:155-159.
41. Kanter IC, Huttner HB, Staykov D, et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008;49:914-920. (Pubitemid 351652431)
42. Stagg CJ, Lang B, Best JG, et al. Autoantibodies to glutamate acid dec-arboxylase in epilepsy patients are associated with a low cortical GABA levels. Epilepsia 2010;51:1898-1901.
43. Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand 2010;121:251-256.
44. Van Baalen A, Hausler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2010;51:1323-1328.
45. Mikaeloff Y, Jambaque I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo-encephalitis. Epilepsy Res 2006;69:67-79.
46. Wilder-Smith EP, Lim EC, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005;34:417-420. (Pubitemid 41290847)
47. Lyon G, Dodge PR, Adams RD. The acute encephalopathies of obscure origin in infants and children. Brain 1961;84:680-708.
48. Costello DJ, Kilbride RD, Cole AJ. Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not? J Neurol Sci 2009;277:26-31.
49. Tan KM, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883-1890. (Pubitemid 351684641)
50. Lalic T, Pettingill P, Vincent A, Capogna M. Human limbic encephalitis serum enhances hippocampal mossy fibre-CA3 pyramidal cell synaptic transmission. Epilepsia 2010 [Epub ahead of print].